Keywords: Multiple sclerosis, Biogen Idec, Elan, Tysabri, Risk stratification analysis, PML

New analysis of risk stratification for Biogen and Elan's Tysabri

Article | 20 May 2012

Print This

US biotech company Biogen Idec (Nasdaq: BIIB) and Ireland-based partner Elan (NYSE: ELN) said that a global risk management program ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in